Special Issue

Lipidomic Profiling of Oxylipins for a Mechanistic Understanding of Inflammatory-Related Diseases

Message from the Guest Editors

The term “oxylipins” refers to a superfamily of signaling lipids generated from the oxygenation of polyunsaturated fatty acids (PUFAs). Similar to cytokines, oxylipins are major mediators of the innate immune response that are involved in infection and inflammation, as well as in the resolution of inflammation. Advances in analytical methods now allow the quantitative profiling of dozens of oxylipins providing a comprehensive systems biology approach for understanding and treating diseases implicating oxylipin signaling. This Special Issue will discuss the potential of lipidomic profiling of oxylipins to provide a mechanistic understanding of inflammatory-related diseases. Studies on changes in oxylipin profiles in patients with inflammatory-related diseases (e.g., cardiometabolic diseases, CVD, immune diseases, cancer, infectious diseases or inflammaging) as well on the modulation of the oxylipin production by anti-inflammatory or pro-resolving therapeutic or dietary approaches are welcome. Clinical or population studies as well as reviews in this topic area will be considered for peer review.

Guest Editors

Dr. Cécile Gladine

Dr. John William Newman

Prof. Dr. Harold M. Aukema

Deadline for manuscript submissions

closed (15 August 2022)

Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/si/96905

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/journal/metabolites

MDPI

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).